Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Sep 17:2020:8872774.
doi: 10.1155/2020/8872774. eCollection 2020.

Primary Sjögren's Syndrome Accompanied by Clinical Features of TAFRO Syndrome

Affiliations
Case Reports

Primary Sjögren's Syndrome Accompanied by Clinical Features of TAFRO Syndrome

Eiji Suzuki et al. Case Rep Rheumatol. .

Abstract

Sjögren's syndrome (SS) is associated with not only sicca symptoms but also various symptoms caused by extraglandular manifestation. The pathophysiology and comorbidities of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly), which is thought to be a variant of multicentric Castleman's disease, are not fully understood, and there are few data on the effectiveness of treatments. We report a patient of SS with TAFRO syndrome-like clinical features. A 52-year-old woman was admitted to our hospital because of abdominal distension. Laboratory data showed thrombocytopenia, and image findings showed massive ascites without evidence of malignant disease as confirmed by cytology. She was diagnosed with SS based on dysfunction of salivary secretion and positivity for anti-Ro/SS-A and La/SS-B antibodies, accompanied by clinical features of TAFRO syndrome based on the presence of anasarca and thrombocytopenia. High-dose corticosteroid for inflammation, anasarca, and thrombocytopenia was not effective. Cyclosporine was administered next, but anasarca and thrombocytopenia did not immediately improve until tolvaptan and eltrombopag were added. Although tolvaptan and eltrombopag were used for only a few months, the patient maintained a good condition with cyclosporine and low-dose prednisolone. In SS patients, activation of antigen-specific T lymphocytes is thought to be an important trigger that accelerates the immune response and is followed by hypercytokinemia. Therefore, using cyclosporine to suppress the activity of T lymphocytes is a reasonable treatment for SS accompanied with TAFRO syndrome-like pathophysiology. It might also be useful to administer tolvaptan or eltrombopag before the effects of immunosuppressants appear. If refractory inflammation with anasarca, thrombocytopenia, or lymphadenopathy is observed in an SS patient, complications with TAFRO syndrome-like pathophysiology should be considered.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Chest X-ray on admission showing bilateral dullness of the costophrenic angles.
Figure 2
Figure 2
Computed tomography revealing enlargement of the axillary lymph nodes and right pleural effusion (a) and ascites around the liver and spleen (b) and in the pelvic cavity (c).
Figure 3
Figure 3
Clinical course of treatment and response of the patient. CRP, C-reactive protein; mPSL, methylprednisolone; PLT, platelet.

Similar articles

Cited by

References

    1. Sumida T. Sjögren’s syndrome. Internal Medicine. 1999;38(2):165–168. doi: 10.2169/internalmedicine.38.165. - DOI - PubMed
    1. Tsuboi H., Asashima H., Takai C., et al. Primary and secondary surveys on epidemiology of Sjögren’s syndrome in Japan. Modern Rheumatology. 2014;24(3):464–470. doi: 10.3109/14397595.2013.843765. - DOI - PubMed
    1. Ramos-Casals M., Tzioufas A. G., Font J. Primary Sjögren’s syndrome: new clinical and therapeutic concepts. Annals of the Rheumatic Diseases. 2004;64(3):347–354. doi: 10.1136/ard.2004.025676. - DOI - PMC - PubMed
    1. Asmussen K., Andersen V., Bendixen G., Schiodt M., Oxholm P. A new model for classification of disease manifestations in primary Sjogren’s syndrome: evaluation in a retrospective long-term study. Journal of Internal Medicine. 1996;239(6):475–482. doi: 10.1046/j.1365-2796.1996.418817000.x. - DOI - PubMed
    1. Nocturne G., Mariette X. Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nature Reviews Rheumatology. 2013;9(9):544–546. doi: 10.1038/nrrheum.2013.110. - DOI - PubMed

Publication types